Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin

International Journal of Oncology

Volumn 11, Issue 3, 1997, Pages 539-542

  Fink, Daniel ^a   Nebel, Sibylle ^a   Aebi, Stefan ^a   Nehmé, Alissar ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cisplatin; DNA mismatch repair; Drug resistance; MSH2; PMS2

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA;

ANIMAL CELL; ARTICLE; BASE MISPAIRING; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG RESISTANCE; EMBRYO; EMBRYO CELL; FIBROBLAST; GENE DISRUPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

EID: 0030855734     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.3.539     Document Type: Article

References (23)

1. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M and Kudelka A: Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13: 1584-1588, 1995.
2. Kolodner R: Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10: 1433-1442, 1996.
3. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong O, Hsuan JJ and Jiricny J: GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268: 1912-1914, 1995.
4. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R and Fishel R: HMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 93: 13629-13634, 1996.
5. Fishel R and Kolodner RD: Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382-395, 1995.
6. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P: An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424-6428, 1993.
7. Griffin S, Branch P, Xu YZ and Karran P: DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 33: 4787-4793, 1994.
8. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090, 1996.
9. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996.
10. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA and Boland CR: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLHI mutation. Cancer Res 54: 4308-4312, 1994.
11. De Wind N, Dekker M, Berns A, Radman M and te Riele H: Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrccombination, and predisposition to cancer. Cell 82: 321-330, 1995.
12. Baker SM, Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, Elliott EA, Yu J, Ashley T, Arnheim N, Flavell RA and Liskay RM: Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis: Cell 82: 309-319, 1995.
13. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistlca D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screnning. J Natl Cancer Inst 82: 1107-1112, 1990.
14. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Woodrich M, Campbell H, Mayo J and Boyd M: Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell line. J Natl Cancer Inst 83: 757-766, 1990.
15. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD and Kunkel TA: Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063-6070, 1995.
16. 2 cell cycle checkpoint. Cancer Res 55: 3721-3725, 1995.
17. Mello JA, Acharya S, Fishel R and Essigmann JM: The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3: 579-589, 1996.
18. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93: 6443-6447, 1996.
19. Risinger JI, Umar A, Boyd J, Berchuck A, Kunkel TA and Barrett JC: Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat Genet 14: 102-105, 1996.
20. Li GM and Modrich P: Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci USA 92: 1950-1954, 1995.
21. Andrews PA, Jones JA, Varki NM and Howell SB: Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2: 93-100, 1990.
22. Loeb LA: Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54: 5059-5063, 1994.
23. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O and Rachmilewitz EA: Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88: 4296-4303, 1996.